ProQR Therapeutics (PRQR) Capital Expenditures (2013 - 2022)

ProQR Therapeutics' Capital Expenditures history runs 10 years deep, the most recent figure standing at $1.5 million for Q4 2022.

• In Q4 2022, Capital Expenditures rose 666.42% year-over-year to $1.5 million; the TTM figure through Dec 2022 stood at $689557.5 (up 222.05% YoY), while the FY2025 annual figure was $1.2 million, down 21.64% from the prior year.
• Capital Expenditures came in at $1.5 million for Q4 2022 at ProQR Therapeutics, up from -$248035.5 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q4 2022 to a low of -$378902.3 in Q2 2020.
• A 5-year average of -$84312.7 and a median of -$173532.7 in 2020 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures tumbled 5158046.1% in 2019 and surged 666.42% in 2022, its largest moves.
• ProQR Therapeutics' Capital Expenditures stood at -$30.82 in 2018, then tumbled by 858322.67% to -$264546.2 in 2019, then soared by 46.82% to -$140690.2 in 2020, then plunged by 82.95% to -$257393.5 in 2021, then soared by 666.42% to $1.5 million in 2022.
• According to Business Quant data, Capital Expenditures over the past three periods registered $1.5 million, -$248035.5, and -$246490.1 for Q4 2022, Q3 2022, and Q2 2022 respectively.

Peer Comparison